Featured Video Content
NORMAL AND NEOPLASTIC STEM CELLS
Dr. Irving Weissman, Director, Institute for Stem Cell Biology & Regenerative Medicine AND Stanford Ludwig Center for Cancer Stem Cell Research and Medicine
COVID: OUR LIFE SCIENCES SPUTNIK MOMENT
Dr. Ron DePinho, Immediate Past President, MD Anderson Cancer Center
TRANSFOMRATION IN CANCER DIAGNOSIS AND TREATMENT IN 2020
CMO, National Foundation for Cancer Research
Frm President, Emory & McGill Cancer Centers
Director, Darwin Institute
APPLYING FINANCIAL ENGINEERING TO CANCER
Dr. Andrew Lo, Director, Laboratory for Financial Engineering, MIT
PANEL: COVID'S AFFECTS ON CLINICAL TRIALS
Moderated By: Roy Herbst, Co-Head of Immunology at Yale Cancer Center
ENHCANCED DRUG DEVELOPMENT USING DRUG MECHANISM BIOMARKERS
Director DCTD Program Pharmacodyrnamic Biomarkers
REPURPOSING THE POLIO VACCINE IN THE WAR AGAINST COVID
Dr. Robert Gallo, Co-Founder and Director, The Institute of Human Virology (IHV) and Co-Founder HIV Virus
COVID: OUR LIFE SCIENCES SPUTNIK MOMENT
Dr. Jerome Kim, Director General of the International Vaccine Institute
BIOSECURITY: A MULTI-DIMENSIONAL CHALLENGE OF ESCALATING COMLEXITY AND URGENCY
George Poste, Professor, ASU; Former Head of R&D, GSK; Defense Science Board of the U.S. Department of Defense
MedInvest to Host Pharma and Biotech Investor Conference September 15-16, 2026.
The upcoming Meeting of the MedInvest Pharma and Biotech Investor Conference will be hosted in New York City on September 15-16, 2026. The National Cancer Institute, National Institutes of Health, Citizens Bank, and Hogan Lovells Law Firm will be the Presenting Partners.
The event will feature keynote talks, panels, and corporate presentations from over 40 companies. Over 100 investors spanning venture capital, public funds, foundations, family offices and government grant making entities are expected to attend either virtually or in person.
Rewinding the Cellular Clock: The Origin and Mission of Rejuvenation Technologies
The story of Rejuvenation Technologies begins with a profound scientific breakthrough and a sudden shift in academic focus. In 1998, human telomeres—the protective caps at the ends of DNA strands that dictate cellular aging—were artificially extended for the very first time. John Ramunas was a fourth-year Electrical Engineering student when he read about this incredible feat. Recognizing the massive implications for human longevity and disease prevention, he immediately switched his major to Biochemistry.
Hua Medicine: Restoring Glucose Sensitivity for Durable Diabetes Control
Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China, and publicly listed on The Stock Exchange of Hong Kong (ticker:2552). Hua Medicine’s cornerstone product is dorzagliatin, a global first-in-class glucokinase activator (GKA).
While many therapies only address the downstream consequences of dysregulated blood glucose, i.e., elevated blood sugar levels, dorzagliatin’s core innovation lies in repairing the impaired function and expression of glucokinase (GK) in patients with Type 2 diabetes, improving glucose sensitivity from the source and helping restore glucose homeostasis.
Arcadia Medicine: Developing safer entactogenic compounds to treat challenging psychiatric conditions
For decades, neuropsychiatrists have recognized the profound therapeutic potential of entactogens (compounds which promote empathy and emotional openness), but their clinical path was blocked by legal, scientific, and regulatory barriers. In recent years, a thaw in research has allowed these revolutionary therapies to be evaluated in clinical studies, with an eventual goal of FDA approval and commercialization.
Based in San Francisco, Arcadia is working to develop a new generation of safe and effective entactogens. Its strategy is focused on engineering novel forms of molecules with an existing history of human use to improve clinical efficacy while reducing physical and psychological risks. This vision has led to the development of Arcadia’s lead candidate, AM-1002, a non-racemic formulation of MDMA.